Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3200 participants.
Also called NCT04045665
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,200 participants
- Sponsor
- Registry
-
NCT04045665
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Brazil, Canada, Germany, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT04045665. Randomized; no masking; primary purpose treatment. Start 2019-12-13 (actual); primary completion 2026-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- Acronym
- PACES
- Condition
- Atrial Fibrillation
- Condition
- Stroke
- Condition
- Bleeding
- Intervention (Drug)
- Antiplatelet-only strategy
- Intervention (Drug)
- Oral Anticoagulant plus background antiplatelet therapy
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- Vanderbilt University Medical Center
Record details
- Record id
cardio:ct-nct04045665- Content hash
e814aaa752531c4c8ede82f354f70656bf3fdb3275f3b1ffa4b9b666aeb3d304